WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are ...

There are multiple chapters near you. Select your preferred chapter.

New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS ® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen. ROCKVILLE, ...

Aurinia Pharmaceuticals (AUPH) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early ...

The Lupus Foundation of America (LFA) is proud to honor two exceptional lupus researchers at the 2024 Evelyn V. Hess ...

Then there’s physical activity: Many of the symptoms of lupus, such as joint pain, fatigue, and depression, may make patients ...

The company said the patient, an African American-Asian woman diagnosed with lupus nephritis, received fludarabine-free ...

Fate Therapeutics (FATE) stock rallied 37% Monday on positive Phase 1 study data for its cell therapies FT819 and FT522. Read ...

Experts have called for greater awareness of lupus to promote better access to healthcare for those living with the condition ...

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...